Anesthesia & Respiratory Devices Market Value Predicted To Reach US$ 43.7 Billion By 2027: Acumen Research And Consulting
31 mars 2021 12h24 HE
|
Acumen Research and Consulting
LOS ANGELES, March 31, 2021 (GLOBE NEWSWIRE) -- The Global Anesthesia & Respiratory Devices Market is expected to grow at a CAGR of around 6.5% from 2020 to 2027 and reach the market value of...
Novartis secures exclusive rights for potential acute respiratory distress syndrome cell therapy
19 nov. 2020 16h30 HE
|
Novartis International AG
Novartis enters into exclusive worldwide license with Mesoblast to develop, commercialize and manufacture remestemcel-L for treatment of acute respiratory distress syndrome (ARDS) and other...
Vitalograph Launch Powerful New In2itive e-Diary for Global Clinical Trials
14 oct. 2020 09h00 HE
|
Vitalograph
Next generation eCOA device with integrated respiratory assessment Vitalograph are delighted to announce that their most powerful ever In2itive...
Grey Cloak Tech Inc. Launches Customer Relationship Management (CRM) Program to Increase Sales and Retention
08 oct. 2020 08h30 HE
|
Grey Cloak Tech Inc.
LAS VEGAS, Oct. 08, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – Grey Cloak Tech Inc. (OTC: GRCK – soon to be Healthy Extracts Inc. pending a corporate name change), a company engaged in proprietary...
Grey Cloak Tech Inc. Introduces ‘Clinical IMMUNE™’ to Combat Respiratory Symptoms
06 oct. 2020 08h30 HE
|
Grey Cloak Tech Inc.
LAS VEGAS, Oct. 06, 2020 (GLOBE NEWSWIRE) -- via NetworkWire – Grey Cloak Tech Inc. (OTC: GRCK – name change pending to Healthy Extracts Inc.), today announces that its BergaMet NA subsidiary has...
Novartis post hoc analysis shows high-dose Enerzair® Breezhaler® reduces asthma exacerbations versus medium-dose, complementing key pivotal IRIDIUM study findings
07 sept. 2020 01h15 HE
|
Novartis International AG
High-dose, once-daily Enerzair® Breezhaler® [IND/GLY/MF] reduced asthma exacerbation rates by 21% (moderate or severe) and 31% (severe) versus medium-dose, over 52 weeks1 Once-daily Enerzair...
Novartis receives EC approval for Enerzair® Breezhaler®, including the first digital companion (sensor and app) that can be prescribed alongside a treatment for uncontrolled asthma in the EU
07 juil. 2020 01h15 HE
|
Novartis International AG
European Commission approves once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) in the EU, the first-in-class LABA/LAMA/ICS fixed-dose combination for patients whose asthma is uncontrolled with...
Novartis receives simultaneous approval for five new products from Japanese Ministry of Health, Labour and Welfare, offering Japanese patients a broad range of novel treatment options
29 juin 2020 02h45 HE
|
Novartis International AG
Basel, June 29, 2020 — Novartis Pharma K.K. (“Novartis Pharma”) today announced that the Japanese Ministry of Health, Labour and Welfare (MHLW) simultaneously approved five new treatment options for...
Novartis Phase IIIb ARGON study meets primary endpoint in a comparison of Enerzair® Breezhaler® (QVM149) versus a free combination of two existing inhaled treatments in uncontrolled asthma
05 juin 2020 01h15 HE
|
Novartis International AG
Once-daily Enerzair® Breezhaler® (QVM149; IND/GLY/MF) met primary endpoint, demonstrating non-inferiority to a free combination of twice-daily Sal/Flu plus once-daily tiotropium (Tio), in improving...
Liquidia Appoints Tushar Shah, M.D., as Chief Medical Officer
18 mai 2020 07h15 HE
|
Liquidia Technologies, Inc.
RESEARCH TRIANGLE PARK, N.C., May 18, 2020 (GLOBE NEWSWIRE) -- Liquidia Technologies, Inc. (Nasdaq: LQDA), a late-stage clinical biopharmaceutical company focused on the development and...